Metadata Search
Actinium Pharmaceuticals
Page 1 of 17 results
Sort by: relevance publication year Download as CSV

European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards

Journal Article published Mar 2016 in Biology of Blood and Marrow Transplantation volume 22 issue 3 on pages 514 to 519

Research funded by National Cancer Institute | National Heart, Lung, and Blood Institute | National Institute of Allergy and Infectious Diseases | Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028) | Actinium Pharmaceuticals | Allos Therapeutics | Amgen

Authors: Chloe Anthias, Paul V. O'Donnell, Deidre M. Kiefer, Jean Yared, Maxim Norkin, Paolo Anderlini, Bipin N. Savani, Miguel A. Diaz, Menachem Bitan, Joerg P. Halter, Brent R. Logan, Galen E. Switzer, Michael A. Pulsipher, Dennis L. Confer, Bronwen E. Shaw

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma

Journal Article published Jan 2017 in Biology of Blood and Marrow Transplantation volume 23 issue 1 on pages 60 to 66

Research funded by Medac GmbH | Kiadis Pharma | Takeda Oncology | Sigma-Tau Pharmaceuticals | StemCyte | TerumoBCT | Leukemia and Lymphoma Society | Soligenix, Inc. | Milliman USA, Inc. | Actinium Pharmaceuticals | Therakos | Fred Hutchinson Cancer Research Center | Gentium SpA | WellPoint | Gamida Cell Teva Joint Venture Ltd. | Seattle Genetics | Sanofi | Ariad Pharmaceuticals | University of Utah | NHLBI and NCI (5U10HL069294) | Health Research, Inc. Roswell Park Cancer Institute | University of Minnesota | Perkin Elmer, Inc. | Onyx Pharmaceuticals | Blue Cross and Blue Shield Association | Osiris Therapeutics | Optum Healthcare Solutions, Inc. | Genentech | Genzyme | Miltenyi Biotec, Inc. | Teva Neuroscience, Inc. | Stemsoft Software, Inc. | National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) (U24-CA076518) | The Medical College of Wisconsin | Otsuka America Pharmaceutical | Health Resources and Services Administration (HHSH250201200016C) | Celgene | Merck | St. Baldrick's Foundation | Swedish Orphan Biovitrum | Be The Match Foundation | Tarix Pharmaceuticals | Amgen | HistoGenetics, Inc. | Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028) | Chimerix, Inc. | Jeff Gordon Children's Foundation | Incyte Corporation | Allos Therapeutics | GlaxoSmithKline | Fresenius-Biotech North America, Inc. | Remedy Informatics

Authors: Robert F. Cornell, Veronika Bachanova, Anita D'Souza, Kwang Woo-Ahn, Michael Martens, Jiaxing Huang, A. Samer Al-Homsi, Saurabh Chhabra, Edward Copelan, Miguel-Angel Diaz, Cesar O. Freytes, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Gerhard Hildebrandt, Rammurti T. Kamble, Mohamed Kharfan-Dabaja, Tamila Kindwall-Keller, Hillard M. Lazarus, David I. Marks, Taiga Nishihori, Richard F. Olsson, Ayman Saad, Saad Usmani, David H. Vesole, Jean Yared, Tomer Mark, Yago Nieto, Parameswaran Hari

In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children

Journal Article published Dec 2015 in Biology of Blood and Marrow Transplantation volume 21 issue 12 on pages 2173 to 2179

Research funded by Medac GmbH | National Marrow Donor Program | Kiadis Pharma | National Cancer Institute (U24-CA076518) | U.S. Public Health Service | Roswell Park Cancer Institute | Sigma-Tau Pharmaceuticals | Medical College of Wisconsin | TerumoBCT | Soligenix, Inc. | Actinium Pharmaceuticals | Therakos | Fred Hutchinson Cancer Research Center | Gentium SpA | WellPoint | Gamida Cell Teva Joint Venture Ltd. | Seattle Genetics | Sanofi | National Institute of Allergy and Infectious Diseases | Ariad Pharmaceuticals | University of Utah | University of Minnesota | Perkin Elmer, Inc. | Onyx Pharmaceuticals | Blue Cross and Blue Shield Association | National Heart, Lung, and Blood Institute (5U10HL069294) | Miltenyi Biotec | Millennium: The Takeda Oncology Co. | Osiris Therapeutics | Optum Healthcare Solutions, Inc. | HistoGenetics | Genentech | Genzyme | Teva Neuroscience, Inc. | Stemsoft Software, Inc. | Health Research | Otsuka America Pharmaceutical | Health Resources and Services Administration (HHSH250201200016C) | Celgene | Merck | St. Baldrick's Foundation | Swedish Orphan Biovitrum | Be The Match Foundation | Tarix Pharmaceuticals | Amgen | Milliman | Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028) | Chimerix, Inc. | Jeff Gordon Children's Foundation | Incyte Corporation | Allos Therapeutics | GlaxoSmithKline | Fresenius-Biotech North America, Inc. | Remedy Informatics

Authors: Doris M. Ponce, Mary Eapen, Rodney Sparapani, Tracey A. O'Brien, Ka Wah Chan, Junfang Chen, John Craddock, Kirk R. Schultz, John E. Wagner, Miguel-Angel Perales, Juliet N. Barker

Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research

Journal Article published Dec 2015 in Biology of Blood and Marrow Transplantation volume 21 issue 12 on pages 2154 to 2159

Research funded by Medac GmbH | National Marrow Donor Program | Kiadis Pharma | National Cancer Institute (U24-CA076518, HHSH250201200016) | U.S. Public Health Service | Roswell Park Cancer Institute | Sigma-Tau Pharmaceuticals | StemCyte | Medical College of Wisconsin | TerumoBCT | Soligenix, Inc. | Actinium Pharmaceuticals | Therakos | Fred Hutchinson Cancer Research Center | Gentium SpA | WellPoint | Gamida Cell Teva Joint Venture Ltd. | Seattle Genetics | Sanofi | National Institute of Allergy and Infectious Diseases | Ariad Pharmaceuticals | University of Utah | University of Minnesota | Perkin Elmer, Inc. | Onyx Pharmaceuticals | Blue Cross and Blue Shield Association | National Heart, Lung, and Blood Institute (5U10HL069294) | Miltenyi Biotec | Millennium: The Takeda Oncology Co. | Osiris Therapeutics | Optum Healthcare Solutions, Inc. | HistoGenetics | Genentech | Genzyme | Teva Neuroscience, Inc. | Stemsoft Software, Inc. | Health Research | Otsuka America Pharmaceutical | Health Resources and Services Administration | Celgene | Leukemia and Lymphoma Society of Canada | Merck | St. Baldrick's Foundation | Swedish Orphan Biovitrum | Be The Match Foundation | Tarix Pharmaceuticals | Amgen | Milliman | Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028) | Chimerix, Inc. | Jeff Gordon Children's Foundation | Incyte Corporation | Allos Therapeutics | GlaxoSmithKline | Fresenius-Biotech North America, Inc. | Remedy Informatics

Authors: Michael J. Burke, Michael R. Verneris, Jennifer Le Rademacher, Wensheng He, Hisham Abdel-Azim, Allistair A. Abraham, Jeffery J. Auletta, Mouhab Ayas, Valerie I. Brown, Mitchell S. Cairo, Ka Wah Chan, Miguel A. Diaz Perez, Christopher C. Dvorak, R. Maarten Egeler, Lamis Eldjerou, Haydar Frangoul, Gregory M.T. Guilcher, Robert J. Hayashi, Ahmed Ibrahim, Kimberly A. Kasow, Wing H. Leung, Richard F. Olsson, Michael A. Pulsipher, Niketa Shah, Nirali N. Shah, Elizabeth Thiel, Julie-An Talano, Carrie L. Kitko

Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers

Journal Article published Mar 2016 in Biology of Blood and Marrow Transplantation volume 22 issue 3 on pages 520 to 527

Research funded by Medac GmbH | National Marrow Donor Program | Kiadis Pharma | National Cancer Institute (U24-CA076518) | U.S. Public Health Service | Roswell Park Cancer Institute | Sigma-Tau Pharmaceuticals | StemCyte | Medical College of Wisconsin | TerumoBCT | Leukemia and Lymphoma Society | Soligenix, Inc. | Actinium Pharmaceuticals | Therakos | Fred Hutchinson Cancer Research Center | Gentium SpA | WellPoint | Gamida Cell Teva Joint Venture Ltd. | Seattle Genetics | Sanofi | National Institute of Allergy and Infectious Diseases | Ariad Pharmaceuticals | University of Utah | University of Minnesota | Perkin Elmer, Inc. | Onyx Pharmaceuticals | Blue Cross and Blue Shield Association | National Heart, Lung, and Blood Institute (5U10HL069294) | Miltenyi Biotec | Millennium: The Takeda Oncology Co. | Osiris Therapeutics | Optum Healthcare Solutions, Inc. | HistoGenetics | Genentech | Genzyme | Teva Neuroscience, Inc. | Stemsoft Software, Inc. | Health Research | Otsuka America Pharmaceutical | Health Resources and Services Administration (HHSH250201200016C) | Celgene | Merck | St. Baldrick's Foundation | Swedish Orphan Biovitrum | Be The Match Foundation | Tarix Pharmaceuticals | Amgen | Milliman | Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028) | Chimerix, Inc. | Jeff Gordon Children's Foundation | Incyte Corporation | Allos Therapeutics | GlaxoSmithKline | Fresenius-Biotech North America, Inc. | Remedy Informatics

Authors: Chloe Anthias, Bronwen E. Shaw, Deidre M. Kiefer, Jane L. Liesveld, Jean Yared, Rammurti T. Kamble, Anita D'Souza, Peiman Hematti, Matthew D. Seftel, Maxim Norkin, Zachariah DeFilipp, Kimberly A. Kasow, Muneer H. Abidi, Bipin N. Savani, Nirali N. Shah, Paolo Anderlini, Miguel A. Diaz, Adriana K. Malone, Joerg P. Halter, Hillard M. Lazarus, Brent R. Logan, Galen E. Switzer, Michael A. Pulsipher, Dennis L. Confer, Paul V. O'Donnell

Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis

Journal Article published May 2017 in Biology of Blood and Marrow Transplantation volume 23 issue 5 on pages 853 to 856

Research funded by Medac GmbH | National Marrow Donor Program | Kiadis Pharma | Roswell Park Cancer Institute | Sigma-Tau Pharmaceuticals | StemCyte | Medical College of Wisconsin | TerumoBCT | Leukemia and Lymphoma Society | Soligenix, Inc. | Actinium Pharmaceuticals | Therakos | Fred Hutchinson Cancer Research Center | Gentium SpA | WellPoint | Gamida Cell Teva Joint Venture Ltd. | Seattle Genetics | Sanofi | Ariad Pharmaceuticals | University of Utah | NHLBI and NCI (5U10HL069294) | University of Minnesota | Perkin Elmer, Inc. | Onyx Pharmaceuticals | Blue Cross and Blue Shield Association | Miltenyi Biotec | Millennium: The Takeda Oncology Co. | Osiris Therapeutics | Optum Healthcare Solutions, Inc. | HistoGenetics | Genentech | Genzyme | Teva Neuroscience, Inc. | Stemsoft Software, Inc. | National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) (U24-CA076518) | Otsuka America Pharmaceutical | Health Resources and Services Administration (HHSH250201200016C) | Celgene | Merck | St. Baldrick's Foundation | Swedish Orphan Biovitrum | Be The Match Foundation | Tarix Pharmaceuticals | Amgen | Milliman | Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028) | Chimerix, Inc. | Jeff Gordon Children's Foundation | Incyte Corporation | Allos Therapeutics | GlaxoSmithKline | Fresenius-Biotech North America, Inc. | Remedy Informatics

Authors: Mehdi Hamadani, Abraham S. Kanate, Alyssa DiGilio, Kwang Woo Ahn, Sonali M. Smith, Jong Wook Lee, Ernesto Ayala, Nelson Chao, Parameswaran Hari, Javier Bolaños-Meade, Ronald Gress, Niels Smedegaard Anderson, Yi-Bin Chen, Umar Farooq, Gary Schiller, Jean Yared, Anna Sureda, Timothy S. Fenske, Horatiu Olteanu

Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age

Journal Article published Aug 2017 in Biology of Blood and Marrow Transplantation volume 23 issue 8 on pages 1327 to 1334

Research funded by Novartis Pharmaceuticals Corporation | National Marrow Donor Program | Patient-Centered Outcomes Research Institute | Roswell Park Cancer Institute | Takeda Oncology | Medical College of Wisconsin | Pfizer | Leukemia and Lymphoma Society | Actinium Pharmaceuticals | Bristol-Myers Squibb | Cerus Corporation | Alexion Pharmaceuticals | Fred Hutchinson Cancer Research Center | WellPoint | Seattle Genetics | Sanofi | Janssen Scientific Affairs, LLC | Gamida Cell Ltd. | NHLBI and NCI (5U10HL069294) | University of Minnesota | Perkin Elmer, Inc. | Onyx Pharmaceuticals | Swedish Orphan Biovitrum, Inc. | Miltenyi Biotec | Optum Healthcare Solutions, Inc. | MesoScale Diagnostics, Inc. | HistoGenetics | Spectrum Pharmaceuticals | Genentech | Atara Biotherapeutics, Inc. | Mesoblast | Genzyme | Medac, GmbH | Telomere Diagnostics, Inc. | Sunesis Pharmaceuticals, Inc. | Jazz Pharmaceuticals | National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) (5U24-CA076518) | Gilead Sciences | Otsuka America Pharmaceutical | Neovii Biotech NA, Inc. | Health Resources and Services Administration (HHSH250201200016C) | Cellular Dynamics International, Inc. | Celgene | AstraZeneca | Merck | MedImmune | St. Baldrick's Foundation | Be The Match Foundation | Amgen | Office of Naval Research (N00014-15-1-0848, N00014-16-1-2020) | Chimerix, Inc. | Jeff Gordon Children's Foundation | Bluebird Bio, Inc. | Astellas Pharma US | Incyte Corporation | Otsuka Pharmaceutical

Authors: Lynda M. Vrooman, Heather R. Millard, Ruta Brazauskas, Navneet S. Majhail, Minoo Battiwalla, Mary E. Flowers, Bipin N. Savani, Görgün Akpek, Mahmoud Aljurf, Rajinder Bajwa, K. Scott Baker, Amer Beitinjaneh, Menachem Bitan, David Buchbinder, Eric Chow, Christopher Dandoy, Andrew C. Dietz, Lisa Diller, Robert Peter Gale, Shahrukh K. Hashmi, Robert J. Hayashi, Peiman Hematti, Rammurti T. Kamble, Kimberly A. Kasow, Morris Kletzel, Hillard M. Lazarus, Adriana K. Malone, David I. Marks, Tracey A. O'Brien, Richard F. Olsson, Olle Ringden, Sachiko Seo, Amir Steinberg, Lolie C. Yu, Anne Warwick, Bronwen Shaw, Christine Duncan

Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival

Journal Article published Mar 2018 in Biology of Blood and Marrow Transplantation volume 24 issue 3 on pages 478 to 485

Research funded by National Cancer Institute (U24-CA076518) | National Heart, Lung, and Blood Institute (5U10HL069294) | National Institute of Allergy and Infectious Diseases | Health Resources and Services Administration (HHSH250201200016C) | Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028) | Actinium Pharmaceuticals | Allos Therapeutics | Amgen

Authors: Myo Htut, Anita D'Souza, Amrita Krishnan, Benedetto Bruno, Mei-Jie Zhang, Mingwei Fei, Miguel Angel Diaz, Edward Copelan, Siddhartha Ganguly, Mehdi Hamadani, Mohamed Kharfan-Dabaja, Hillard Lazarus, Cindy Lee, Kenneth Meehan, Taiga Nishihori, Ayman Saad, Sachiko Seo, Muthalagu Ramanathan, Saad Z. Usmani, Christina Gasparetto, Tomer M. Mark, Yago Nieto, Parameswaran Hari

Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis

Journal Article published Apr 2018 in Biology of Blood and Marrow Transplantation volume 24 issue 4 on pages 827 to 831

Research funded by National Cancer Institute | Patient-Centered Outcomes Research Institute | Anonymous donation to the Medical College of Wisconsin | Takeda Oncology | Medical College of Wisconsin | Millennium, the Takeda Oncology Co. | Actinium Pharmaceuticals | Cerus Corporation | Spectrum Pharmaceuticals, Inc. | Pfizer, Inc | Fred Hutchinson Cancer Research Center | Pharmacyclics, LLC | PIRCHE AG | Seattle Genetics | National Institute of Allergy and Infectious Diseases | Immucor | Janssen Scientific Affairs, LLC | Bristol Myers Squibb Oncology | Amneal Biosciences | Kite Pharma, Inc. | Gamida Cell Ltd. | University of Minnesota | National Heart, Lung, and Blood Institute | Swedish Orphan Biovitrum, Inc. | MesoScale Diagnostics, Inc. | Juno Therapeutics; Karyopharm Therapeutics, Inc. | National Marrow Donor Program; | Atara Biotherapeutics, Inc. | Mesoblast | Medac, GmbH | Miltenyi Biotec, Inc. | Telomere Diagnostics, Inc. | Shire | Sunesis Pharmaceuticals, Inc. | Jazz Pharmaceuticals | Gilead Sciences | Neovii Biotech NA, Inc. | Health Resources and Services Administration (HHSH250201200016C) | Celgene | Merck | MedImmune | St. Baldrick's Foundation | Be The Match Foundation | Sanofi Genzyme | Amgen | HistoGenetics, Inc. | bluebird bio, Inc. | Office of Naval Research (N00014-17-1-2388, N00014-16-1-2020)) | Chimerix, Inc. | Astellas Pharma US | Angiocrine Bioscience, Inc. | Incyte Corporation | Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. – Japan

Authors: Basem M. William, Tao Wang, Michael D. Haagenson, Katharina Fleischhauer, Michael Verneris, Katharine C. Hsu, Marcos J. de Lima, Marcelo Fernandez-Viña, Stephen R. Spellman, Stephanie J. Lee, Brian T. Hill

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

Journal Article published Feb 2016 in Biology of Blood and Marrow Transplantation volume 22 issue 2 on pages 248 to 257

Research funded by Medac GmbH | National Marrow Donor Program | Kiadis Pharma | National Cancer Institute (U24-CA076518) | Roswell Park Cancer Institute | Takeda Oncology | Sigma-Tau Pharmaceuticals | StemCyte | Medical College of Wisconsin | TerumoBCT | Leukemia and Lymphoma Society | Soligenix, Inc. | Actinium Pharmaceuticals | Therakos | Fred Hutchinson Cancer Research Center | Gentium SpA | WellPoint | Gamida Cell Teva Joint Venture Ltd. | Seattle Genetics | Sanofi | National Institute of Allergy and Infectious Diseases | Ariad Pharmaceuticals | University of Utah | University of Minnesota | Perkin Elmer, Inc. | Onyx Pharmaceuticals | Blue Cross and Blue Shield Association | National Heart, Lung, and Blood Institute (5U10HL069294) | Miltenyi Biotec | Osiris Therapeutics | Optum Healthcare Solutions, Inc. | HistoGenetics | Genentech | Genzyme | Teva Neuroscience, Inc. | Stemsoft Software, Inc. | Health Research | Otsuka America Pharmaceutical | Health Resources and Services Administration (HHSH250201200016C) | Celgene | Merck | St. Baldrick's Foundation | Swedish Orphan Biovitrum | Be The Match Foundation | Tarix Pharmaceuticals | Amgen | Milliman | Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028) | Chimerix, Inc. | Jeff Gordon Children's Foundation | Incyte Corporation | Allos Therapeutics | GlaxoSmithKline | Fresenius-Biotech North America, Inc. | Remedy Informatics

Authors: Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C. Medeiros, Philippe Armand, Zhen-Huan Hu, Taiga Nishihori, Mahmoud D. Aljurf, Görgün Akpek, Jean-Yves Cahn, Mitchell S. Cairo, Jan Cerny, Edward A. Copelan, Abhinav Deol, César O. Freytes, Robert Peter Gale, Siddhartha Ganguly, Biju George, Vikas Gupta, Gregory A. Hale, Rammurti T. Kamble, Thomas R. Klumpp, Hillard M. Lazarus, Selina M. Luger, Jane L. Liesveld, Mark R. Litzow, David I. Marks, Rodrigo Martino, Maxim Norkin, Richard F. Olsson, Betul Oran, Attaphol Pawarode, Michael A. Pulsipher, Muthalagu Ramanathan, Ran Reshef, Ayman A. Saad, Wael Saber, Bipin N. Savani, Harry C. Schouten, Olle Ringdén, Martin S. Tallman, Geoffrey L. Uy, William A. Wood, Baldeep Wirk, Waleska S. Pérez, Minoo Batiwalla, Daniel J. Weisdorf